US Supreme Court rules for Teva over multiple sclerosis drug patent

By REUTERS
January 20, 2015 17:20

WASHINGTON - The US Supreme Court on Tuesday ruled for Teva Pharmaceutical Industries Ltd in its fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug, by sending the case back to a lower court for further review.

On a 7-2 vote, the justices said that the US Court of Appeals for the Federal Circuit had not used the correct approach in analyzing whether the patent in question, due to expire in September 2015, was valid.


Related Content

Breaking news
May 25, 2018
Two retired French spies suspected of handing secrets to foreign power

By REUTERS